文献速递炎症性肠病

优化炎症性肠病生物制剂选择:基于联合分析开发在线患者决策辅助工具

Optimizing Selection of Biologics in Inflammatory Bowel Disease: Development of an Online Patient Decision Aid Using Conjoint Analysis.
PubMed 文献 · Am J Gastroenterol · 2017-12-05

研究采用自适应选择联合分析调查640例炎症性肠病患者(溃疡性结肠炎304例,克罗恩病336例),量化生物制剂属性在决策中的相对重要性,并据此开发在线患者决策辅助工具。回归分析显示人口学和疾病特征大多不能预测患者偏好,主要例外是IBD类型:克罗恩病患者更可能将副作用特征列为最重要(OR 1.63,95%CI 1.16-2.30),溃疡性结肠炎患者更可能重视疗效(OR 1.41,95%CI 1.01-2.00)。结论认为生物制剂决策高度个体化,该在线工具(www.ibdandme.org)可用于支持共享决策。

要点

  • 640例IBD患者完成联合分析调查,其中溃疡性结肠炎304例、克罗恩病336例。
  • 克罗恩病患者较溃疡性结肠炎患者更可能将副作用特征列为最重要(OR 1.63,95%CI 1.16-2.30)。
  • 溃疡性结肠炎患者较克罗恩病患者更可能重视疗效(OR 1.41,95%CI 1.01-2.00)。

核心结论

  • 生物制剂决策高度个体化,人口学和疾病特征难以预测个体偏好,提示IBD患者具有独特性且难以进行统计分类。
  • 本研究产生的在线决策工具(www.ibdandme.org)或可由患者用于支持与医生的共享决策并优化个体化生物制剂选择。

研究设计与样本

  • 对IBD患者实施自适应选择联合分析调查,量化生物制剂属性(如疗效、副作用特征、给药方式和作用机制)在决策中的相对重要性。
  • 联合分析软件通过计算各属性的部分价值效用确定个体患者偏好。
  • 采用回归分析判断人口学和疾病特征(如IBD类型和严重程度)是否预测患者决策方式。
  • 共640例患者完成调查,其中溃疡性结肠炎304例、克罗恩病336例。

主要发现

  • 回归分析中人口学和IBD特征未预测个体患者偏好,主要例外是IBD类型。
  • 与溃疡性结肠炎相比,克罗恩病患者更可能报告副作用特征为最重要(OR 1.63,95%CI 1.16-2.30)。
  • 溃疡性结肠炎患者更可能重视治疗疗效(OR 1.41,95%CI 1.01-2.00)。

临床怎么用

  • 作者认为在线决策工具(www.ibdandme.org)或可由患者用于支持与医生的共享决策并优化个体化生物制剂选择。
  • 原文未据此给出其他推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Recent drug approvals have increased the availability of biologic therapies for inflammatory bowel disease (IBD), making it difficult for patients with ulcerative colitis (UC) and Crohn's disease (CD) to navigate treatment options. Here we developed a conjoint analysis to examine patient decision-making surrounding biologic medicines for IBD. We used the results to create an online patient decision aid that generates a unique "preferences report" for each patient to assist with shared decision-making with their provider. METHODS: We administered an adaptive choice-based conjoint survey to IBD patients that quantifies the relative importance of biologic attributes (e.g., efficacy, side effect profile, mode of administration, and mechanism of action) in decision making. The conjoint software determined individual patient preferences by calculating part-worth utilities for each attribute. We conducted regression analyses to determine if demographic and disease characteristics (e.g., type of IBD and severity) predicted how patients made decisions. RESULTS: 640 patients completed the survey (UC=304; CD=336). In regression analyses, demographics and IBD characteristics did not predict individual patient preferences; the main exception was IBD type. When compared to UC, CD patients were more likely to report side effect profile as most important (odds ratio (OR) 1.63, 95% confidence interval (CI) 1.16-2.30). Conversely, those with UC were more likely to value therapeutic efficacy (OR 1.41, 95% CI 1.01-2.00). CONCLUSIONS: Biologic decision-making is highly personalized; demographic and disease characteristics poorly predict individual preferences, indicating that IBD patients are unique and difficult to statistically categorize. The online decision tool resulting from this study (www.ibdandme.org) may be used by patients to support shared decision-making and optimize personalized biologic selection with their provider.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Almario CV, Keller MS, Chen M, et al. Optimizing Selection of Biologics in Inflammatory Bowel Disease: Development of an Online Patient Decision Aid Using Conjoint Analysis. Am J Gastroenterol. 2017. PMID: 29206816. doi:10.1038/ajg.2017.470

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。